A

AbbVie

Global biopharmaceutical company developing medicines

Associate Director - International Market Access and Pricing, Oncology

Full-TimeUpdated on 10/23/2026
$141.5k - $268.5k/yr+ Long-term incentive program
Senior
Bachelor's, Master's
Mettawa, IL, USA
Hybrid
Growth & MarketingProduct Marketing

About the job

Requirements
  • At least 5 years of biotechnology, pharmaceutical, payer, market access, pricing and reimbursement, commercial strategy, health economics and outcomes research, or related experience.
  • Global or international payer and access experience, preferably in oncology at the global, regional, or key-market level.
  • Ability to translate clinical, health economic, payer, and competitive insights into access recommendations.
  • Ability to collaborate with and influence Area, Affiliate, and internal partners across commercial, development, medical, regulatory, pricing, health economics and outcomes research, health technology assessment, and government affairs functions.
  • Strong leadership, interpersonal, critical thinking, analytical, and project management skills.
  • A bachelor's degree is required.
Responsibilities
  • Support the Director, Oncology Solid Tumor Lead in developing and executing Elahere international access, pricing, and reimbursement strategy, including second-line platinum-resistant ovarian cancer launch execution and strategy refinement, lifecycle planning, and Area and Affiliate support.
  • Contribute to Integrated Access Strategy development by synthesizing clinical, health economics and outcomes research, payer, pricing, reimbursement, policy, competitive, Area, and Affiliate insights into strategic recommendations.
  • Develop and maintain core access deliverables, including value propositions, payer value stories, value dossiers, payer objection handlers, negotiation pathways, evidence gap assessments, Area and Affiliate tools, and second-line platinum-resistant and platinum-sensitive ovarian cancer launch and lifecycle materials.
  • Partner with Area and Affiliate teams at key clinical, regulatory, evidence, label, lifecycle, and market-development milestones to assess local pricing, reimbursement, and patient access implications.
  • Advance second-line platinum-sensitive ovarian cancer maintenance launch preparation and lifecycle access planning through strategic assessments and mitigation strategies, including payer risk assessment and cross-functional alignment on evidence, pricing, sequencing, and market readiness.
  • Collaborate with Pricing, health technology assessment Strategy, health economics and outcomes research, Commercial, Competitive Intelligence, Medical Affairs, Regulatory, Government Affairs, Area, and Affiliate teams to inform payer strategy and reimbursement planning.
  • Support Elahere Value and Access Team operations, including agenda development, decision tracking, alignment, and follow-up on key access, pricing, evidence, and launch-readiness actions.
  • Assess and monitor pricing, reimbursement, payer, health technology assessment, competitive, clinical, and policy developments across priority markets, translating implications into access strategy, evidence planning, competitive readiness, Area and Affiliate execution, and mitigation planning.
  • Manage assigned access workstreams, including vendor coordination, budget management, purchasing support, documentation, compliance activities, and project records.
Desired Qualifications
  • An advanced degree in a scientific, clinical, business, health economics, or related discipline.
  • Strong oncology disease-area knowledge, with solid tumor experience preferred.
  • Experience evaluating payer trends, access success drivers, competitive dynamics, and evidence requirements across priority international markets.
  • Experience developing payer materials, Integrated Access Strategies, health technology assessment-related deliverables, and launch or lifecycle access plans.
  • Knowledge of pricing policy, pricing governance, reimbursement regulations, and healthcare systems in key international markets.
  • Understanding of regulatory, evidence, and label implications for pricing, reimbursement, and patient access.
  • Strong business acumen, executive communication, presentation, and writing skills.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.